BPIFA1 and asthma: We identified a potential five-biomarker panel (BPIFA1, MUC5AC, CAMP, CTSG, and ANXA1) that illustrates the inflammatory activity of asthma in sputum and could improve asthma phenotyping, providing valuable insights into personalized treatment approaches.